A phase IIb clinical trial for Galera Therapeutics’ GC4419 met its primary endpoint, demonstrating a significant (p=0.024), clinically meaningful and dose-dependent reduction in the duration of severe oral mucositis in patients with head and neck cancer receiving chemoradiation.
The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, as a monotherapy for the treatment of resectable locally advanced head-and-neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumors express PD-L1 with a Combined Positive Score ≥1.
